Incidence and Survivability of Acute Lymphocytic Leukemia Patients in the United States: Analysis of SEER Data Set from 2000-2019
- 1 Department of Biology, Rockhurst University, Kansas City, Missouri, USA
- 2 Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA
Abstract
The main goal of this research is to assess the impact of race, age at diagnosis, sex, and phenotype on the incidence and survivability of acute lymphocytic leukemia (ALL) among patients in the United States. By taking these factors into account, the study aims to explore how existing cancer registry data can aid in the early detection and effective treatment of ALL in patients. Our hypothesis was that statistically significant correlations exist between race, age at which patients were diagnosed, sex, and phenotype of the ALL patients, and their rate of incidence and survivability data were evaluated using SEER*Stat statistical software from National Cancer Institute. Analysis of the incidence data revealed that a higher prevalence of ALL was among the Caucasian population. The majority of ALL cases (59%) occurred in patients aged between 0 to 19 years at the time of diagnosis, and 56% of the affected individuals were male. The B-cell phenotype was predominantly associated with ALL cases (73%). When analyzing survivability data, it was observed that the 5-year survival rates slightly exceeded the 10-year survival rates for the respective demographics. Survivability rates of African Americans patients were the lowest compared to Caucasian, Asian, Pacific Islanders, Alaskan Native, Native Americans and others. Survivability rates progressively decreased for older patients. Moreover, this study investigated the typical treatment methods applied to ALL patients, mainly comprising chemotherapy, with occasional supplementation of radiation therapy as required. The study demonstrated the considerable efficacy of chemotherapy in enhancing patients’ chances of survival, while those who remained untreated faced a less favorable prognosis from the disease. Although a significant amount of data and information exists, this study can help doctors in the future by diagnosing patients with certain characteristics. It will further assist the health care professionals in screening potential patients and early detection of cases. This could also save the lives of elderly patients who have a higher mortality rate from this disease.
- Mayo Foundation for Medical Education and Research (2021, February 10) Acute Lymphocytic Leukemia. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/symptoms-causes/syc-20369077
- American Cancer Society (2018, October 17) What Is Acute Lymphocytic Leukemia (All)? Acute Lymphocytic Leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/what-is-all.html
- NHS (2019, September 30) Acute Lymphoblastic Leukaemia. NHS Choices. https://www.nhs.uk/conditions/acute-lymphoblastic-leukaemia
- American Cancer Society (2018, October 17) Risk Factors for Acute Lymphocytic Leukemia (ALL). https://www.cancer.org/cancer/acute-lymphocytic-leukemia/causes-risks-prevention/risk-factors.html
- National Cancer Institute (2019, March 7) Risk Factors: Radiation. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation
- U.S. Department of Health and Human Services (n.d.) Human T-Cell Leukemia Virus Type 1—About the Disease. Genetic and Rare Diseases Information Center. https://rarediseases.info.nih.gov/diseases/9645/human-t-cell-leukemia-virus-type-1
- Imperial College London. Cancer-Causing Virus HTLV-1 Changes DNA Loops to “Affect Tens of Thousands of Genes”. ScienceDaily. https://www.sciencedaily.com/releases/2018/06/180627160355.htm
- The University of Kansas Cancer Center (2020, October 15) What You Should Know about Acute Lymphoblastic Leukemia: University of Kansas Cancer Center. https://www.kucancercenter.org/news-room/blog/2020/10/what-you-should-know-acute-lymphoblastic-leukemia
- National Cancer Institute (2021, November 19) Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)—Patient Version. https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq
- Litzow, M.R. and Ferrando, A.A. (2015, August 13) How I Treat T-Cell Acute Lymphoblastic Leukemia in Adults. Blood , 126, 833-841. https://doi.org/10.1182/blood-2014-10-551895 https://ashpublications.org/blood/article/126/7/833/34458/How-I-treat-T-cell-acute-lymphoblastic-leukemia-in
- American Cancer Society (2020, May 1) Chemotherapy Side Effects. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/chemotherapy-side-effects.html
- Kadan-Lottick, N.S., Ness, K.K., Bhatia, S. and Gurney, J.G. (2003, October 15) Survival Variability by Race and Ethnicity in Childhood Acute Lymphoblastic Leukemia. JAMA , 290, 2008-2014. https://pubmed.ncbi.nlm.nih.gov/14559954/ https://doi.org/10.1001/jama.290.15.2008